Pharma BD Deal Intelligence
Cheap, milestone-weighted nephrology discovery option
Full analysis, sources & comparables →AstraZeneca and CSPC Pharmaceutical Group announced (early July 2026) a drug-discovery collaboration to develop nucleic-acid (siRNA) candidates against two undisclosed kidney-disease pathways, combining CSPC's siRNA chemistry with AI-driven molecular design. AstraZeneca pays CSPC USD 30 million upfront, with up to USD 540 million in development milestones and up to USD 1.2 billion in sales-linked payments (up to ~USD 1.77 billion total), plus royalties. AstraZeneca holds global / ex-China licensing options while CSPC retains domestic rights for one asset. The pact extends AstraZeneca's expanding relationship with CSPC across obesity, cardiovascular and chronic disease. (Announcement date reported as July 2-3, 2026.)
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / CSPC Pharmaceutical Group Ltd. (this deal) | 2026 | $1.8B | 59 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · AstraZeneca PLC deals · Nephrology deals